Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) on January 21 and set a price ...

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

Details for the presentations are as follows: Majo NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The global Ultrasound Market, The global ultrasound market, valued at US$8.65 billion in 2023, is forecasted to grow at a robust CAGR of 6.8%, reaching US$9.32 billion in 2024 and an impressive US$13.

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...